Back

Discussant review - ARIES

13 May 2024 (13:53 - 13:57)
Organised by: Logo
Congress Presentation Part of: Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy Ventricular Assist Devices HFA Premium Access Heart Failure 2024 Heart Failure Association (HFA)

About the speaker

Photo
Doctor Owais Dar

Guy's and St Thomas' NHS Trust Hospitals, London (United Kingdom of Great Britain & Northern Ireland)

9 More presentations in this session

Presentation thumbnail
Outcomes with aspirin avoidance after implantation of a Fully Magnetically Levitated LVAD in patients with coronary, cerebral or peripheral vascular disease: the ARIES HM3 randomized clinical trial
Professor F. Gustafsson (Pleasanton, US)
Slides Video
Presentation thumbnail
Semaglutide therapy and diuretic use in obesity-related HFpEF: insights from the STEP-HFpEF programme
Professor S. Verma (Toronto, CA)
Slides Video
Presentation thumbnail
Discussant review - STEP-HFpEF Programme
Assistant Professor D. Farmakis (Athens, GR)
Slides Video
Presentation thumbnail
Aficamten for the treatment of symptomatic obstructive hypertrophic cardiomyopathy: SEQUOIA-HCM an international multicenter phase 3 trial
Doctor M. Maron (Burlington, US)
Slides Video
Presentation thumbnail
Discussant review - Quantitative Understanding of Obstruction Impact of Aficamten in HCM
Professor P. Elliott (London, GB)
Slides Video

Access the full session

Session thumbnail
Late breaking clinical trials: LVAD, HFpEF and hypertrophic cardiomyopathy
Video

The Event

Event poster

Heart Failure 2024

13 May 2024 13:53 CET
You may be interested in
thumbnail
Congress Presentation
Reducing residual risk in left ventricular assist device carriers: lessons from ARIES-HM3 trial
thumbnail
Congress Presentation
Aspirin and hemocompatibility related adverse events after LVAD implantation in patients with diabetes mellitus, obesity and atrial fibrillation: the ARIES-HM3 randomized clinical trial
thumbnail
Congress Presentation
Outcomes with aspirin avoidance after implantation of a Fully Magnetically Levitated LVAD in patients with coronary, cerebral or peripheral vascular disease: the ARIES HM3 randomized clinical trial

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources